Corbus Pharmaceuticals Holdings (CRBP) EBIT (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly EBIT of -$24.4 million for Q3 2025, down 57.48% year-over-year from -$57.4 million in Q3 2024, and down 27.49% quarter-over-quarter from -$19.2 million in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) EBIT (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBIT history runs 13 years deep, the most recent figure standing at -$24.4 million for Q3 2025.
- In Q3 2025, EBIT fell 57.48% year-over-year to -$24.4 million; the TTM figure through Sep 2025 stood at -$75.9 million (down 64.32% YoY), while the FY2024 annual figure was -$48.7 million, down 8.08% from the prior year.
- EBIT for Q3 2025 stood at -$24.4 million, down from -$19.2 million in the prior quarter.
- The five-year high for EBIT was -$8.2 million in Q3 2022, with the low at -$24.4 million in Q3 2025.
- The 5-year median for EBIT is -$12.3 million (2022), against an average of -$13.3 million.
- The sharpest annual moves came in 2021 and 2025: EBIT jumped 59.16% in 2021, then tumbled 105.5% in 2025.
- Corbus Pharmaceuticals Holdings' EBIT stood at -$10.0 million in 2021, then fell by 7.99% to -$10.8 million in 2022, then rose by 6.42% to -$10.1 million in 2023, then dropped by 24.75% to -$12.6 million in 2024, then sank by 93.71% to -$24.4 million in 2025.
- Business Quant data shows CRBP's EBIT at -$24.4 million in Q3 2025, -$19.2 million in Q2 2025, and -$19.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.42 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -19.78 Mn |
| Dec 31, 2024 | -12.61 Mn |
| Sep 30, 2024 | -15.51 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -9.62 Mn |
| Dec 31, 2023 | -10.10 Mn |
| Sep 30, 2023 | -9.49 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -17.30 Mn |
| Dec 31, 2022 | -10.80 Mn |
| Sep 30, 2022 | -8.18 Mn |
| Jun 30, 2022 | -12.34 Mn |
| Mar 31, 2022 | -8.52 Mn |
| Dec 31, 2021 | -10.00 Mn |
| Sep 30, 2021 | -13.88 Mn |
| Jun 30, 2021 | -16.70 Mn |
| Mar 31, 2021 | -15.41 Mn |
| Dec 31, 2020 | -20.81 Mn |